Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Aprea TherapeuticsINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT03552549 | SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) | terminated | Phase 2 / Phase 3 | 126 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 24, 2019 |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01191034 | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 2 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01723813 | Peptide Vaccinations Plus GM-CT-01 in Melanoma | terminated | Phase 1 / Phase 2 | 6 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00365937 | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | terminated | Phase 1 / Phase 2 | 19 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01813214 | The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma | terminated | Phase 2 | 5 | Georgetown UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02314143 | Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib | terminated | Phase 2 | 48 | GlaxoSmithKlineINDUSTRY | 2 | Feb 18, 2019 | clinicaltrials |
| NCT01542255 | Metronomic Therapy in Patients With Metastatic Melanoma | terminated | Phase 2 | 7 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01350401 | Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 4 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02050321 | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | terminated | Phase 2 | 2 | University of ArizonaOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00961376 | Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC) | terminated | Phase 2 | 5 | Providence Health & ServicesOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01453361 | Phase II FANG™ in Advanced Melanoma | terminated | Phase 2 | 18 | Gradalis, Inc.INDUSTRY | 1 | May 24, 2018 | clinicaltrials |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT01702896 | Interleukin-2 in Metastatic Melanoma | terminated | Phase 2 | 8 | Western Regional Medical CenterOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01543464 | Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients | terminated | Phase 2 | 41 | Inge Marie SvaneOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT01689974 | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | terminated | Phase 2 | 10 | NYU Langone HealthOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT01721603 | Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | terminated | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01740401 | CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma | terminated | Phase 2 | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01495988 | Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | terminated | Phase 2 | 10 | Melanoma Research Foundation Breakthrough ConsortiumOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT01009515 | Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | terminated | Phase 2 | 19 | New Mexico Cancer Research AllianceOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT02111863 | Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT01696045 | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | terminated | Phase 2 | 14 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 29, 2017 | clinicaltrials |
| NCT01138410 | Study of a DNA Immunotherapy to Treat Melanoma | terminated | Phase 1 / Phase 2 | 35 | Scancell LtdINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01042366 | Dendritic Cells (DC) Vaccine for Metastatic Melanoma | terminated | Phase 2 | 16 | John KirkwoodOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT01271907 | Drosophila-generated CTL | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00849875 | A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients | terminated | Phase 2 | 48 | GlaxoSmithKlineINDUSTRY | 2 | Jul 12, 2017 | clinicaltrials |
| NCT00925132 | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | terminated | Phase 1 / Phase 2 | 39 | University of IowaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01701037 | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | terminated | Phase 2 | 13 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01586195 | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | terminated | Phase 2 | 31 | Genentech, Inc.INDUSTRY | 1 | May 25, 2017 | clinicaltrials |
| NCT01551693 | STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT01754376 | Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma | terminated | Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | terminated | Phase 1 / Phase 2 | 9 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01026324 | Dinaciclib in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00707161 | Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma | terminated | Phase 2 | 12 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 27, 2017 | clinicaltrials |
| NCT00601861 | Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer | terminated | Phase 2 | 1 | Novo Nordisk A/SINDUSTRY | 1 | Mar 1, 2017 | clinicaltrials |
| NCT01705392 | Bevacizumab vs Dacarbazine in Metastatic Melanoma | terminated | Phase 2 | 2 | Haukeland University HospitalOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT01820364 | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma(LOGIC) | terminated | Phase 2 | 15 | Array BioPharmaINDUSTRY | 6 | Jan 9, 2017 | clinicaltrials |
| NCT00068666 | Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System | terminated | Phase 2 | 41 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01888081 | A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma | terminated | Phase 1 / Phase 2 | 2 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 23, 2016 | clinicaltrials |
| NCT01973608 | MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma | terminated | Phase 2 | 12 | EMD SeronoINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | terminated | Phase 1 / Phase 2 | 28 | Array BioPharmaINDUSTRY | 4 | Sep 13, 2016 | clinicaltrials |
| NCT01092728 | Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | terminated | Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2019source: clinicaltrials